This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Mecloxamine is a medication indicated in combination with caffeine, ergotamine, and acetaminophen for the treatment of headaches and migraines.
- Generic Name
- Mecloxamine
- DrugBank Accession Number
- DB15790
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Mecloxamine (DB15790)
- Weight
- Average: 317.86
Monoisotopic: 317.1546421 - Chemical Formula
- C19H24ClNO
- Synonyms
- Mecloxamine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination for symptomatic treatment of Cluster headache Combination Product in combination with: Acetaminophen (DB00316), Ergotamine (DB00696), Caffeine (DB00201) •••••••••••• ••••• •••••• Used in combination for symptomatic treatment of Migraine Combination Product in combination with: Ergotamine (DB00696), Caffeine (DB00201), Acetaminophen (DB00316) •••••••••••• ••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Mecloxamine citrate 26G46G752S 56050-03-4 NWXYYVAVFTZHND-UHFFFAOYSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AVMIGRAN FİLM TABLET, 20 ADET Mecloxamine citrate (20 mg) + Acetaminophen (325 mg) + Caffeine (80 mg) + Ergotamine tartrate (0.75 mg) Tablet MENARİNİ SAĞLIK VE İLAÇ SAN. VE TİC. A.Ş. 1974-01-15 Not applicable Turkey 
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- U8V8239CRM
- CAS number
- 5668-06-4
- InChI Key
- WILANEPAIMJUCP-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H24ClNO/c1-15(14-21(3)4)22-19(2,16-8-6-5-7-9-16)17-10-12-18(20)13-11-17/h5-13,15H,14H2,1-4H3
- IUPAC Name
- {2-[1-(4-chlorophenyl)-1-phenylethoxy]propyl}dimethylamine
- SMILES
- CC(CN(C)C)OC(C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
References
- General References
- TITCK Product Information: AVMIGRAN (acetaminophen, caffeine, ergotamine tartrate, and mecloxamine citrate) tablet [Link]
- External Links
- ChemSpider
- 2308147
- ChEBI
- 135360
- ChEMBL
- CHEMBL2105171
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00304 mg/mL ALOGPS logP 4.81 ALOGPS logP 4.81 Chemaxon logS -5 ALOGPS pKa (Strongest Basic) 9.1 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 12.47 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 93.99 m3·mol-1 Chemaxon Polarizability 35.61 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-1592000000-2cd5945ae8ec8f7bc1be Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0uxr-1916000000-fd7d67c07fdb157e67c1 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0ap0-9130000000-5063a3e48e3d0a928c37 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0iml-7930000000-c9e46b0adc44476538b6 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-9400000000-61b9a3408a046e6da9fd Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0gb9-0920000000-420ad524e1b632a1a1e5 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 173.74004 predictedDeepCCS 1.0 (2019) [M+H]+ 176.09804 predictedDeepCCS 1.0 (2019) [M+Na]+ 182.19118 predictedDeepCCS 1.0 (2019)
Drug created at August 27, 2020 19:55 / Updated at May 14, 2021 01:08